Our Primary Focus: Patients

We Start Our Programs to Address Unmet Medical Needs that Improve the Quality of Life for Our Patients and their Families

Processa Pharmaceuticals is committed to improving the quality of life for patients with unmet medical needs. Our approach to development, always starts with the needs of the patient, from acquisition through development we are focused on intelligently designing and completing trials with critical data that permit efficient evaluation of the risk/benefit of our pharmacological solutions. We believe our de-risked approach leads to a higher probability of success; and when patients win, we all win.

About Our Company

How is Processa different?

Our leadership team was brought together by a common goal: to help patients suffering from life-threatening and life-compromising chronic diseases. The starting point for all our programs begins with unmet medical needs for patients and caregivers. We allocate our resources to accelerate development of these life improving solutions. Working together for over 30 years, the leadership team has garnered a unique approach to develop therapies today through learning and applying their R&D and regulatory expertise to efficiently position drugs for approval success.

View Management Team

View Board of Directors

View Product Development Team

Our Mission: To Develop Effective Pharmacological Solutions

Processa Pharmaceuticals Inc. is a development-stage pharmaceutical company that uses a unique approach to develop not discover drugs that help in the treatment of oncology and other high unmet medical need diseases with unparalleled regulatory science and clinical expertise.

Our drug candidates are intended for patients who have limited treatment options for their conditions. Our leading candidates include:

Metastatic Colorectal and Breast Cancer

PCS6422 aims to make the cornerstone of chemotherapy safer and more effective.

Ulcerative Necrobiosis Lipoidica (NL)

PCS499 aims on a durable solution for chronic Ulcerative Necrobiosis Lipoidica.


PCS12852 aims on providing a safer and more effective treatment for gastroparesis and GI motility.